Equities research analysts expect Zogenix, Inc. (NASDAQ:ZGNX) to post ($0.92) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Zogenix’s earnings, with estimates ranging from ($1.23) to ($0.63). Zogenix reported earnings per share of ($0.87) in the same quarter last year, which would indicate a negative year-over-year growth rate of 5.7%. The firm is expected to report its next quarterly earnings results on Tuesday, March 5th.
On average, analysts expect that Zogenix will report full year earnings of ($3.75) per share for the current year, with EPS estimates ranging from ($4.30) to ($2.81). For the next financial year, analysts anticipate that the company will post earnings of ($2.22) per share, with EPS estimates ranging from ($4.24) to ($0.39). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Zogenix.
Get Zogenix alerts:Several analysts have recently commented on the company. Zacks Investment Research downgraded Zogenix from a “buy” rating to a “hold” rating in a research note on Saturday, November 17th. BidaskClub raised Zogenix from a “hold” rating to a “buy” rating in a research note on Wednesday, January 9th. Mizuho reissued a “buy” rating and issued a $69.00 price objective on shares of Zogenix in a research note on Thursday, December 6th. Piper Jaffray Companies assumed coverage on Zogenix in a research note on Monday, November 5th. They issued an “overweight” rating for the company. Finally, Leerink Swann assumed coverage on Zogenix in a research note on Monday, November 12th. They issued an “outperform” rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Zogenix has an average rating of “Buy” and an average price target of $70.00.
In other news, Director Cam L. Garner sold 5,625 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $50.00, for a total value of $281,250.00. Following the completion of the transaction, the director now directly owns 4,756 shares of the company’s stock, valued at $237,800. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Cam L. Garner sold 12,405 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $46.85, for a total value of $581,174.25. Following the completion of the transaction, the director now directly owns 218 shares of the company’s stock, valued at $10,213.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 143,593 shares of company stock valued at $6,516,009. 4.60% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ZGNX. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Zogenix by 20.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,956 shares of the company’s stock valued at $108,000 after acquiring an additional 496 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Zogenix in the third quarter valued at approximately $109,000. FNY Investment Advisers LLC grew its holdings in Zogenix by 3,900.0% during the third quarter. FNY Investment Advisers LLC now owns 3,000 shares of the company’s stock valued at $148,000 after purchasing an additional 2,925 shares during the period. Great West Life Assurance Co. Can grew its holdings in Zogenix by 44.9% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,382 shares of the company’s stock valued at $189,000 after purchasing an additional 1,668 shares during the period. Finally, Prudential Financial Inc. bought a new position in Zogenix during the third quarter valued at $219,000.
Shares of Zogenix stock traded up $0.61 on Tuesday, hitting $52.60. The company had a trading volume of 294,372 shares, compared to its average volume of 447,590. The company has a market cap of $2.05 billion, a PE ratio of -16.28 and a beta of 2.05. Zogenix has a 1 year low of $33.43 and a 1 year high of $62.75.
Zogenix Company Profile
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Recommended Story: The basics of gap trading strategies
Get a free copy of the Zacks research report on Zogenix (ZGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment